Cohn R J, Schwyzer R, Hesseling P B, Poole J E, Naidoo J, Van Heerden C
Department of Paediatrics, University of the Witwatersrand, South Africa.
Am J Hematol. 1993 Aug;43(4):246-50. doi: 10.1002/ajh.2830430403.
We report the use of alpha 2b-interferon in 15 children with symptomatic, chronic idiopathic thrombocytopenic purpura, who did not respond to standard therapy. The platelet count increased in nine children during therapy. In six children the increase lasted less than 6 weeks. An increased platelet count was seen when a higher dose was used in two of four initial nonresponders. One responder who relapsed had an identical response when retreated with the same dose. No significant side effects were documented. Further studies are required to establish the optimal dose and administration schedule of alpha 2b-interferon for use in children with chronic idiopathic thrombocytopenic purpura.
我们报告了对15名患有症状性慢性特发性血小板减少性紫癜且对标准治疗无反应的儿童使用α2b干扰素的情况。治疗期间9名儿童的血小板计数有所增加。6名儿童的血小板计数增加持续时间不到6周。在最初无反应的4名儿童中有2名使用更高剂量时血小板计数增加。1名复发的反应者再次使用相同剂量治疗时出现了相同的反应。未记录到明显的副作用。需要进一步研究以确定α2b干扰素用于慢性特发性血小板减少性紫癜儿童的最佳剂量和给药方案。
